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Expression of the growth hormone gene is due to the presence of the pituitary-specific transcription factor
GHF-1/Pit-1. The action of the thyroid hormone T3 is mediated by nuclear receptors that regulate transcription
by interaction with DNA elements located near promoters of the regulated genes. In this study, we show that
T3 inhibits expression of the GHF-1/Pit-1 gene in rat pituitary GH4C1 cells by a novel mechanism that involves
transcriptional interference with other regulatory elements of the promoter. Sequences between bp 290 and
2200 of the rat GHF-1/Pit-1 gene which do not contain a hormone response element but contain two cyclic
AMP-responsive elements mediate most of the repressive effect of T3. The hormone reduces basal levels of
GHF-1/Pit-1 promoter activity and antagonizes its response to cyclic AMP and the tumor promoter TPA
(12-O-tetradecanoylphorbol-13-acetate). A similar repression is found with a heterologous promoter that
contains four copies of the cyclic AMP-responsive element motif. This regulation provides a novel example of
the cross-talk between the thyroid hormone receptor and the signal transduction pathways used by different
hormones and growth factors. Additionally, T3 interferes with in vitro binding of GHF-1/Pit-1 to a positive
autoregulatory element located at bp 245 to 263 and has a detectable inhibitory effect on the activity of a
promoter construct which extends to bp 290 of 5*-flanking DNA. The regulation of the transcription factor
provides a novel example of negative transcriptional regulation by thyroid hormones.
The tissue-specific expression of the prolactin and growth
hormone (GH) genes is dependent upon the presence of the
pituitary-specific transcription factor GHF-1/Pit-1. The proxi-
mal promoters of both genes contain related regulatory ele-
ments to which this factor, a member of the homeobox POU
family of DNA-binding proteins, binds with high affinity (8, 9,
12, 19, 26, 29). Analysis of the GHF-1/Pit-1 gene promoter
indicates the presence of an element highly homologous to the
GHF-1/Pit-1 binding sites in the GH and prolactin promoters
which mediates positive autoregulation of its own expression
(34) and a negative element that attenuates its expression (14).
The GHF-1/Pit-1 gene promoter also contains two cyclic AMP
(cAMP)-responsive elements (CREs) (14, 34) which mediate
transcriptional actions of cAMP (34) and are binding sites for
the cAMP-responsive transcription factor CREB (36, 37, 56).
Thyroid hormone is an important regulator of GH produc-
tion both in vivo and in cultured pituitary somatotrophic cells
(22, 33, 50, 55). Thyroid hormone actions are mediated by
nuclear receptors, the product of c-erbA proto-oncogenes,
which function as ligand-inducible transcription factors by
binding to response elements which are normally located in the
59-flanking region of regulated genes (10, 24, 58). In addition
to mediating cell-specific expression, the GH gene promoter
also contains the cis elements modulating transcription in re-
sponse to the thyroid hormone triiodothyronine (T3). Se-
quences between bp 2167 and 2190 function as a thyroid
hormone response element (TRE) and mediate stimulation by
T3 (10).
In addition to stimulating transcription, the nuclear recep-
tors can also selectively inhibit the expression of certain genes.
Negative regulation of transcription can involve binding to
negative response elements, as in the case of the regulation of
thyroid-stimulating hormone gene expression by T3 (5, 13, 16,
17, 39, 54), but it can also be a consequence of interference
with binding sites for other regulatory proteins in the regulated
promoter (1, 18, 25, 36, 45) or even result from a direct inter-
action with other nuclear proteins, such as the components of
the AP-1 complex (27, 31, 38, 40, 47, 57, 60), without requiring
binding to DNA.
In this study we have examined the possibility that besides
binding to the TRE, the T3 receptor could influence rat GH
gene transcription by modulating GHF-1/Pit-1 gene expres-
sion. Our results show that, contrary to its effect on GH gene
expression, T3 decreases GHF-1/Pit-1 mRNA and protein lev-
els in pituitary GH4C1 cells. This decrease is a consequence of
an inhibition of the activity of the GHF-1/Pit-1 promoter de-
spite the lack of a TRE in this region and most likely results
from transcriptional interference with the CREs as well as
from interference with binding of the transcription factor to
the autoregulatory element. These results exemplify a novel
cross-talk between the nuclear receptor pathway and the mem-
brane signal transduction pathway, leading to negative tran-
scriptional regulation by thyroid hormones.
MATERIALS AND METHODS
Plasmids. GHF-1-CAT constructs containing progressive 59 deletions (bp
2400, 2200, and 290) of the rat GHF-1/Pit-1 promoter have been described
previously (34). In the plasmids 2400rGHF1-CAT-DCREP, 2400rGHF1-CAT-
DCRED, and 2400rGHF1-CAT-DCREP,D, the proximal CRE, the distal CRE,
and both CREs, respectively, were deleted. The 2400rGHF1-CAT-DCREP con-
struct was obtained by linearization with BsiWI, digestion with S1 nuclease, and
religation. This treatment deletes 4 bp (GTAC) from the proximal CRE
(GTACGTCA) located at bp 2150 to 2157. For construction of the distal and
double CRE mutants, a PstI-SalI fragment (bp 2430 to 115) from the native
construct or the DCREP mutant was subcloned into pBluescript, digested with
AatII, blunt ended with T4 DNA polymerase, religated, and subcloned again in
the parental construct. This process deleted another 4 bp (ACGT) from the
distal CRE (TGACGTCA) located at bp 2193 to 2200. The deletions were
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confirmed by DNA sequencing. The construct 290.1rGHF1-CAT, from which
the positive autoregulatory element was deleted, has been previously described
by McCormick et al. (35). The construct p4xCREtk-CAT is derived from a
pBLCAT2 variant (30) and contains four copies of a synthetic CRE inserted into
the multiple cloning site in front of the thymidine kinase (TK) promoter of
pBLCAT. The CRE sequence is the one present in the c-fos gene at bp260. The
vectors for the retinoic acid (RA) and T3 receptors contain the cDNA sequences
of the a form of the human RA receptor (RAR) (53) or the a form of chick
c-erbA, a thyroid hormone receptor (TR) (23) under the control of the consti-
tutively active Rous sarcoma virus (RSV) promoter. An expression vector for the
CRE-binding protein CREB (36) also has the RSV promoter.
RNA extraction and hybridization. Total RNA was extracted with guani-
dinium isothiocyanate (15). The RNA was run in 1% formaldehyde-agarose gels,
transferred to nylon membranes (Nytran), and hybridized with a 450-bp EcoRI
fragment of a rat GHF-1 cDNA (9) labeled by random oligonucleotide priming.
Hybridizations were done at 428C with 50% formamide, and the more stringent
wash was done at 558C with 0.13 sodium dodecyl sulfate–13 SSC (13 SSC is
0.15 M NaCl plus 0.015 M sodium citrate). After hybridization, the 32P-labeled
probe was stripped off and the blot was rehybridized with a b-actin probe to
correct for the amount of RNA applied. The Northern (RNA) blots were quan-
titated by densitometric scanning of the autoradiographs, and the GHF-1/Pit-1
mRNA data were corrected by the b-actin mRNA levels.
Cell culture and transfections. GH4C1, 235-1, Cos-7, and HeLa cells were
cultured in Dulbecco modified Eagle medium (DMEM) containing 10% fetal
calf serum and were transfected by electroporation as previously described (6,
22). Ten micrograms of the reporter plasmids was mixed with 20 million to 30
million cells and exposed to a high-voltage pulse (200 to 250 V, 960 mF) by using
a Bio-Rad electroporator with a capacitor extender. The cells from each elec-
troporation were split into different culture plates in Dulbecco modified Eagle
medium containing 10% AG1x8 resin-charcoal-stripped newborn calf serum.
Treatments with RA, T3, and/or TPA (12-O-tetradecanoylphorbol-13-acetate)
and forskolin were administered at the concentrations and the times indicated in
the text in this hormone-depleted medium. Each treatment was performed at
least in duplicate cultures that normally showed less than 5% variation in chlor-
amphenicol acetyltransferase (CAT) activity. CAT activity was determined as
previously described (6, 22) by incubation of the cell extracts with [14C]chloram-
phenicol. The unreacted [14C]chloramphenicol and acetylated [14C]chloram-
phenicol were separated by thin-layer chromatography, identified by autoradiog-
raphy, and quantitated. Each experiment was repeated at least two to three
times, with similar relative differences in regulated expression.
Western blot (immunoblot) analysis.One hundred micrograms of GH4C1 cell
extracts was run in a 12% acrylamide gel and transferred to a nitrocellulose
membrane. Nonspecific binding was blocked with 1% nonfat dried milk in Tris-
buffered saline–0.05% Tween 20 at room temperature. The membrane was
rinsed, incubated with a 1/100 dilution of GHF-1/Pit-1 antibody (10) for 3 h,
washed again, and incubated with 125I-labeled protein A.
Immunofluorescence. GH4C1 cells treated with T3 and RA were fixed with
4% paraformaldehyde, washed with phosphate-buffered saline–glycine, and
treated with 0.5% Triton X-100 for 8 min. The cells were incubated with a
nonimmune serum for 5 min to avoid nonspecific binding. The GHF-1 antibody
was added for 1 h, and a second antirabbit antibody complemented with rhoda-
mine was used as a marker.
In vitro transcription and translation. DNAs were linearized with the appro-
priate enzymes, and the transcription reaction was carried out by following the
instructions of the mCAP RNA capping kit from Stratagene. Translation reac-
tions were performed with a rabbit reticulocyte system lacking methionine from
Promega Corporation, using 4 mCi of [35S]methionine (Amersham).
Mobility shift assays. Gel retardation analyses were carried out with nuclear
extracts from GH4C1, HeLa, or Cos-7 cells. The nuclear extracts were obtained
by the method of Andrews and Faller (2). We used as probes oligonucleotides
corresponding to the proximal GHF-1/Pit-1 binding site of the rat GH promoter
(59-CCAGCCATGAATAAATGTATAAGGG-39), to the positive autoregula-
tory element in the GHF-1/Pit-1 promoter (59-AGCTTACATGTATAAATGG
ATTTCCG-39), to a consensus CRE (59GGATCCGAGCCCTGACGTTTACA
CGAGTCAAGCTT-39), to a consensus Sp-1 site (59-GATGTGTGGGAGGAG
CTTCT-39), or to the TRE, TREPAL (59-AGCTCTAGGTCATGACCTGA-39).
For the binding assays, the extracts were incubated on ice for 15 min in a buffer
(20 mM Tris-HCl [pH 7.5], 75 mM KCl, 1 mM dithiothreitol, 5 mg of bovine
serum albumin [BSA], 13% glycerol) containing 3 mg of poly(dI-dC) and then
were incubated for 15 to 20 min at room temperature with approximately 70,000
cpm of double-stranded oligonucleotide end labeled with [32P]ATP, using T4
polynucleotide kinase. For competition experiments, an excess (50:1) of unla-
beled double-stranded oligodeoxynucleotides was added to the binding reaction
mixture. DNA-protein complexes were resolved on 5% polyacrylamide gels in
0.5% Tris-borate-EDTA buffer. The gels were then dried and autoradiographed
at 2708C.
Cos-7 cells were grown in Dulbecco modified Eagle medium containing 10%
fetal calf serum and were transfected by electroporation with 10 mg of expression
vectors for c-erbA (23) or RAR (52). Each binding reaction mixture contained
the same amount of Cos nuclear extract, which was obtained by adding the
appropriate amount of nuclear extract from Cos cells transfected with 10 mg of
an empty noncoding expression vector (RSV-0).
RESULTS
Regulation of GHF-1/Pit-1 mRNA levels in GH4C1 cells.
Total RNA (10 mg) prepared from pituitary GH4C1 cells was
probed with rat GHF-1/Pit-1 cDNA. Figure 1A shows results
of a representative experiment using control cells and cells
treated with 2 nM T3 for 48 h. Northern analysis with the
GHF-1/Pit-1 probe yielded three major signals corresponding
to 1.2, 3.1, and 4 kb; the most abundant form corresponded to
the 3.1-kb mRNA form. Treatment with T3 did not alter b-ac-
tin mRNA. Densitometric scans from different experiments
showed that T3 reduced by two- to threefold the abundance of
FIG. 1. Northern blot analysis of GHF-1/Pit-1 mRNA in GH4C1 cells. (A) The cells were incubated in thyroid hormone-depleted medium, and Northern blot
analysis was performed with 10 mg of total RNA prepared from control cells (C) and from cells incubated with 2 nM T3 for 48 h. The blots were hybridized with a
rat GHF-1 cDNA probe and with a b-actin probe as described in Materials and Methods. The sizes of the GHF-1/Pit-1 transcripts are indicated. (B) GH4C1 cells were
incubated in hormone-depleted medium with increasing concentrations of T3 for 48 h (left panel) or with 2 nM T3 for the times indicated (right panel). GHF-1/Pit-1
mRNA levels were quantified by densitometric scans of Northern blots hybridized sequentially with a GHF-1/Pit-1 cDNA probe and a b-actin probe. The results were
corrected by the amount of b-actin mRNA. (C) Northern blot analysis was performed with 15 mg of total RNA extracted from control cells (C), from cells incubated
with 2 nM T3 or 10 mM RA for 48 h, or from cells incubated with 10 mM forskolin (FK) or 100 nM TPA for 4 h.
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the different forms which were, therefore, similarly decreased
by the hormone.
Figure 1B shows the effect of a 48-h incubation with increas-
ing concentrations of T3 on GHF-1/Pit-1 mRNA levels. The
hormone produced a dose-dependent decrease of the mRNA
levels. This effect was obtained at physiological hormone con-
centrations, since a half-maximal inhibition was found at 0.1 to
0.2 nM, a concentration identical to the estimated Kd of the T3
nuclear receptors. The maximal inhibition (two- to threefold)
was obtained with 2.5 nM T3, which saturates the receptors.
Figure 1B also shows the time course of the effect of 2 nM T3
on GHF-1/Pit-1 mRNA levels. The decrease was detectable
after 8 to 12 h and was maximal between 24 and 48 h, at which
time, in agreement with the data presented in Fig. 1A, it
produced an approximately 2.5-fold reduction.
RA regulates gene expression by binding to nuclear recep-
tors highly homologous to the T3 receptors (21). We have
previously shown that RA regulates expression of the GH gene
and that the TRE also mediates transcriptional regulation of
this gene by RA (6). Figure 1C compares the effects of T3 and
RA on GHF-1/Pit-1 mRNA levels. As can be observed, RA did
not decrease but, rather, increased the levels of GHF-1/Pit-1
transcripts. On the other hand, Fig. 1C also shows the effect of
a 4-h incubation with 10 mM forskolin, which increases intra-
cellular cAMP, on GHF-1/Pit-1 transcripts. As a consequence
of the existence of two binding sites for CREB in the GHF-1/
Pit-1 promoter (14, 34), forskolin significantly increased GHF-
1/Pit-1 mRNA levels. Since these sites may also be recognized
by the AP-1 complex (44, 46), whose expression is stimulated
by protein kinase C, we also examined the influence of the
tumor promoter TPA on GHF-1/Pit-1 gene expression. Incu-
bation with 100 nM TPA for 4 h increased by approximately
fourfold GHF-1/Pit-1 mRNA levels, thus showing that not only
the protein kinase A pathway but also the protein kinase C
pathway is implicated in the regulation of this gene.
Influence of T3 on GHF-1/Pit-1 protein levels. Figure 2
shows that as a consequence of the reduced mRNA levels, the
concentration of the transcription factor was also decreased in
GH4C1 cells treated with T3. The levels of GHF-1/Pit-1 pro-
tein were examined by Western blot analysis and immunoflu-
orescence assays. Protein extracts of control and T3-treated
GH4C1 cells were assayed by using a specific anti-GHF-1 an-
tibody (8). These assays (Fig. 2, right panel) revealed that the
concentration of the expected 33-kDa protein doublet of im-
munoreactive GHF-1/Pit-1 protein was significantly reduced in
the cells incubated with T3 (40 to 60% in two independent
experiments). This decrease was confirmed by immunostaining
(Fig. 2, left panels). In control GH4C1 cells, the nuclei appear
strongly stained, whereas the cytoplasm is barely visible. How-
ever, after T3 treatment, the intensity of the nuclear staining is
strongly reduced, indicating a reduction of GHF-1/Pit-1 protein.
Regulation of the activity of the GHF-1/Pit-1 promoter by
T3. To examine whether the T3-receptor complexes elicit a
direct control of transcription of the GHF-1/Pit-1 gene
through sequences located in the 59-flanking region of the
gene, transient gene expression was performed with recombi-
nants expressing CAT. Figure 3 shows the influence of T3 on
the activity of the 2400rGHF1-CAT, 2200rGHF1-CAT,
FIG. 2. GHF-1/Pit-1 protein expression in GH4C1 cells. (Left panels) Immunofluorescence assays. The cells were incubated in the presence or in the absence of
2 nM T3 for 48 h, fixed, and analyzed by indirect immunofluorescence with an anti-GHF-1 antibody as described in Materials and Methods. (Right panel) Western
blot analysis of GHF-1/Pit-1. Nuclear extracts (100 mg) from control GH4C1 cells (C) and from cells treated with 2 nM T3 for 48 h were probed with the same antibody,
incubated with 125I-labeled protein A, and submitted to autoradiography. The antibody shows some cross-reactivity with BSA. The GHF-1/Pit-1 doublet and BSA are
indicated.
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290rGHF1-CAT, and 290.1rGHF1-CAT constructs. T3 pro-
duced a marked decrease in the activity of the 2400rGHF1-
CAT plasmid which was dose dependent. A maximal inhibition
was found with 2 nM T3 that decreased CAT activity by two-
to fivefold in different experiments. Additionally, the regula-
tion of construct 2400rGHF1-CAT and that of construct
2200rGHF1-CAT by T3 were identical, demonstrating that
the first 200 bp of the 59-flanking region of the gene mediate
regulation by thyroid hormone. In fact, sequences between bp
2200 and 290 were sufficient to mediate a significant tran-
scriptional inhibition of GHF-1/Pit-1 gene expression by T3,
since the effect of the hormone was markedly reduced on the
plasmid extending to bp 290, although a significant inhibition
was found at both hormone concentrations. The effect of T3 on
the activity of a construct (290.1rGHF1-CAT) which does not
contain the positive autoregulatory element was negligible.
This suggests that this element also plays a role in the repres-
sive action of T3 on GHF-1/Pit-1 promoter activity.
To further document the inhibitory action of T3 on the
290rGHF1-CAT construct, we conducted additional experi-
ments in which the GHF-1/Pit-1 promoter was cotransfected
with a vector expressing the T3 receptor (TRa). In the absence
of ligand, receptor overexpression did not induce important
changes in basal CAT levels but potentiated the inhibitory
effect of T3 (Fig. 4). Under these conditions, 2 nM T3 reduced
promoter activity by more than fivefold.
The negative regulation of T3 is specific for this promoter,
since as shown in Table 1, it does not decrease expression of
CAT reporter constructs containing the RSV promoter or a
minimal promoter (pTATA CAT). Additionally, in agreement
with previous reports, this hormone caused a significant in-
crease in the activity of the rat GH promoter (6, 10) and a less
marked stimulation of the TK promoter (43).
Involvement of the CREs in the inhibitory effect of T3 on the
GHF-1/Pit-1 promoter. Analysis of the bp 2200 to 290 frag-
ment of the GHF-1/Pit-1 promoter did not reveal the existence
of a consensus TRE sequence in this region which, however,
contains at bp 2200 to 2193 and 2157 to 2150 the CRE
motifs. In order to examine the possible implications of these
elements for the T3-mediated transcriptional inhibition, we
examined the influence of T3 on the response of 2400rGHF1-
CAT (which contains the CREs) and constructs 290rGHF1-
CAT and290.1rGHF1-CAT (which do not contain the CREs)
to forskolin and TPA. Figure 5 shows that incubation with
forskolin produced a significant increase (more than fivefold)
in the activity of the2400rGHF1-CAT construct and that TPA
induced a stimulation at least as strong as that caused by
forskolin (left panel), thus showing that the observed effect of
the phorbol ester on GHF-1/Pit-1 mRNA levels is secondary to
transcriptional stimulation. The effect of both compounds on
promoter activity was no longer observed in the case of the
290rGHF1-CAT construct (middle panel) or the 290.1r
GHF1-CAT construct (right panel), which suggests that the
CREs also mediate the TPA-mediated increase.
Figure 5 also shows that treatment with T3 reduced basal
promoter activity by approximately threefold. T3 strongly in-
hibited (from seven- to threefold) the TPA-induced activity of
the CRE-containing reporter gene and, although less strongly,
also reduced the response to forskolin (left panel). In agree-
ment with the data presented in Fig. 5, the effect of the hor-
mone on basal activity of the shorter promoter was much less
marked (middle panel), and it was negligible when the auto-
regulatory element was deleted (right panel).
To directly assess the role of the CREs in the T3 effect, these
elements were deleted both individually and together from the
2400rGHF1-CAT construct. Figure 6 compares the responses
of the wild-type and mutated promoters to forskolin and to
TPA in the presence and in the absence of T3. The native
promoter shows a marked response to TPA and forskolin (Fig.
FIG. 3. Influence of T3 on GHF-1/Pit-1 promoter activity. Cells were trans-
fected by electroporation with 10 mg of the 2400rGHF1-CAT, 2200rGHF1-
CAT, 290rGHF1-CAT, and 290.1rGHF1-CAT constructs and incubated in
medium containing 0, 0.5, or 2 nM T3. After 48 h, the cells were harvested and
CAT activity was assayed in the cell lysates. CAT activity determined by the
conversion of [14C]chloramphenicol to its acetylated forms is illustrated. The
data are expressed as the percentage of the activity of the corresponding un-
treated cells and are means 6 standard deviations (SD) for three different
transfections performed in duplicate.
FIG. 4. Influence of overexpression of T3 receptors. GH4C1 cells were co-
transfected with 10 mg of the 290rGHF1-CAT construct and 10 mg of an
expression vector for the a form of the TR (1TR) or 10 mg of an empty
expression vector (2TR). The data are means 6 SD of CAT activity.
TABLE 1. Specificity of the negative effect of T3a
Construct
CAT activity (% acetylation) at indicated
T3 concn
0 nM 0.5 nM 2.0 nM
290rGHF1-CAT 10.5 6 0.6 5.5 6 0.7 4.8 6 1.3
TATA-CAT 1.0 6 0.1 0.9 6 0.1 1.0 6 0.1
RSV-CAT 33.1 6 2.1 30.7 6 0.6 31.5 6 0.9
TK-CAT 9.4 6 0.4 15.4 6 0.3 18.9 6 0.8
rGH-CAT 9.0 6 0.3 28.7 6 2.1 33.9 6 1.7
a GH4C1 cells were transfected with the 290rGHF1-CAT construct and with
other recombinant plasmids expressing CAT under the control of different pro-
moters. TATA-CAT (a minimal promoter), RSV-CAT (the Rous sarcoma virus
promoter), TK-CAT (the thymidine kinase promoter), and rGH-CAT (the rat
growth hormone promoter). After electroporation, the cells were grown in the
absence or in the presence of T3 for 48 h and CAT activity was determined. All
transfections were performed in the same experiments, and the treatments were
done in duplicate. The data are means 6 SD.
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6A). However, as shown in Fig. 6B and C, deletion of either the
proximal or the distal CRE from the 2400rGHF1-CAT con-
struct very strongly reduced TPA- and forskolin-mediated
stimulation (from eight- and fivefold, respectively, to less than
twofold). These results show that both elements act synergis-
tically to increase the response to protein kinase A and protein
kinase C. Activation by forskolin and TPA was totally abol-
ished when both CREs were deleted (Fig. 6D). In agreement
with the results shown in Fig. 5, T3 strongly reduced basal
activity and stimulated activity of the wild-type promoter (Fig.
6A). The negative effect of T3 on basal promoter activity was
markedly reduced (from more than 75 to 30% decrease) in the
absence of either CRE, although the residual response to TPA
and forskolin was still inhibited after incubation with the hor-
mone (Fig. 6B and C). The negative effect of T3 on basal
activity of the mutated promoter lacking both CREs (Fig. 6D)
was similar to that observed in the absence of one of the
individual CREs, since the hormone had a small but detectable
inhibitory effect on CAT levels. This inhibition was also very
similar to that observed with the 290rGHF1-CAT construct
(Fig. 3 to 5).
Further proof of the involvement of the CREs in the stim-
ulatory effect of TPA and the repression caused by T3 on
GHF-1/Pit-1 promoter activity was obtained with a plasmid
containing a tandem repeat of this motif (p4xCREtk-CAT)
ligated to the TK promoter. Figure 7 shows that expression of
this plasmid was significantly increased not only by forskolin
but also by TPA, thus reinforcing the hypothesis that this
response element mediates the TPA-induced increase of
GHF-1/Pit-1 gene expression. In addition, the effect of T3 on
the response of the construct p4xCREtk-CAT was very similar
to that found with the GHF-1/Pit-1 promoter. T3 strongly
reduced the response to TPA (from fourfold in the absence of
hormone to almost basal levels in T3-treated cells) and to
forskolin (from almost fivefold in the absence of hormone to
less than threefold in the presence of T3). However, T3 re-
pression was not observed with the CRE construct in the ab-
sence of TPA or forskolin treatment.
Influence of T3 on the interaction of nuclear proteins with
CREs. In some cases, negative regulation of gene expression by
nuclear receptors involves a mechanism of competitive DNA
binding with other enhancer elements (1, 18, 48). However, as
examined by gel retardation analysis, the T3 receptor does not
bind to the CREs. Binding of in vitro translated receptor to a
TRE (TREPAL) was efficiently abolished by the same se-
quence, whereas an excess of a CRE oligonucleotide did not
decrease the intensity of the retarded bands. Similarly, binding
of nuclear GH4C1 proteins to the CRE was inhibited by this
element but not by TREPAL. In addition, the T3 receptor
(obtained by either in vitro translation or expression in Cos
cells) did not produce the appearance of retarded bands with
the CRE (data not shown).
FIG. 5. T3 inhibits the response of the GHF-1/Pit-1 promoter to cAMP and phorbol esters. GH4C1 cells were used for transient transfection with the constructs
2400rGHF1-CAT, 290rGHF1-CAT, and 290.1rGHF1-CAT. After electroporation, the cells were grown for 48 h in the absence or in the presence of 2 nM T3 and
with 100 nM TPA or 15 mM forskolin (FK) during the last 4 h. CAT activity was quantitated and is expressed as the fold induction over the values obtained with the
corresponding control (C) untreated cells. The data are means 6 SD.
FIG. 6. Implications of the CREs for the inhibitory response to T3. The cells were transfected with 10 mg of the following constructs: 2400rGHF1-CAT, which
contains the native promoter (A); 2400rGHF1-CAT-DCREP, from which the proximal CRE has been deleted (B); 2400rGHF1-CAT-DCRED, which lacks the distal
CRE (C); and 2400rGHF1-CAT-DCREP,D, which lacks both CREs (D). The cells were incubated with TPA or forskolin in the presence or in the absence of T3 as
indicated in the legend to Fig. 5, and CAT activity was determined. The data are means 6 SD obtained in two independent transfections.
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We next examined the possibility that the treatment with T3
could influence the abundance of nuclear proteins bound to
the CRE. For this purpose, we conducted mobility shift assays
with the CRE oligonucleotide and extracts from control
GH4C1 cells and from cells treated with T3. As a control, we
also used an Sp1 site, since the complex generated by this
factor is unaffected by T3. Figure 8 illustrates that incubation
of both DNA fragments with the cell extracts resulted in the
formation of specific retarded bands whose intensity was not
significantly reduced in the cells incubated with T3. Quantifi-
cation of three independent experiments showed less than 20%
reduction in CRE-binding proteins in T3-treated cells. Fur-
thermore, the hormone did not alter the abundance of CRE-
binding proteins when the cells were incubated with the com-
bination of T3 and forskolin or TPA (data not illustrated).
Influence of overexpression of CREB on the regulation of
GHF-1/Pit-1 promoter activity by T3. Since the activity of
CREs is mainly dependent on the transcription factor CREB,
we tested the effect of overexpression of this factor on the
transcriptional interference of the hormone with the GHF-1/
Pit-1 promoter. However, overexpression of CREB did not
abolish the inhibitory effect of T3. Cotransfection of the
2400rGHF1-CAT construct with an expression vector of this
protein (RSV-CREB) further increased the effect of TPA and
forskolin on GHF-1/Pit-1 promoter activity, but T3 produced a
reduction of basal and stimulated expression which was quan-
titatively very similar to that obtained in the absence of exog-
enous CREB. Again, the regulation by T3 of the GHF-1/Pit-1
promoter and that of the 4xCRE-containing construct were
identical, and the hormone reduced the response of the latter
to forskolin and TPA also in the presence of an excess amount
of CREB (data not illustrated).
Influence of the T3 receptor on GHF-1/Pit-1 binding to
DNA. Since the transactivation experiments demonstrated that
T3 had a detectable effect on the activity of the 290rGHF1-
CAT construct, which contains the positive autoregulatory el-
ement for the transcription factor, we next analyzed the influ-
ence of the T3 receptor on GHF-1/Pit-1 binding to DNA. As a
source of GHF-1/Pit-1, we used nuclear extracts from pituitary
235-1 cells which express high levels of this factor and ex-
tremely low levels of TRs (10- to 20-fold less than GH4C1
cells) as well as proteins obtained by in vitro translation. As a
control, HeLa cells that do not express the GHF-1/Pit-1 gene
and have very low receptor levels were also used. Figure 9
shows the influence of the T3 receptors on GHF-1/Pit-1 bind-
ing to the autoregulatory element in the GHF-1/Pit-1 gene
(Fig. 9B) and to the proximal element in the rat GH gene (Fig.
9A and C). Nuclear extracts of 235-1 cells (6 mg) produced a
strong retardation with both GHF-1/Pit-1 binding sites (Fig. 9,
lanes 6 and 15), whereas no protein-DNA complexes were
formed with the same amount of HeLa cell extracts (Fig. 9,
lanes 7 to 9), corresponding to the absence of GHF-1/Pit-1 in
these cells. The addition of 5 mg of extracts from Cos cells
transfected with the TR TRa produced a marked decrease in
the intensity of the retarded band formed with both GHF-1/
Pit-1 DNA binding elements (Fig. 9, lanes 5 and 14) in com-
parison with the samples that received the same amount of
extracts from Cos-7 cells transfected with an empty expression
vector (Fig. 9, lanes 3 and 13). The possibility that the receptor
could compete with GHF-1/Pit-1 for binding to its cognate
sites can be dismissed, since no retardation was observed when
extracts from receptor-transfected cells were mixed with HeLa
extracts (Fig. 9, lane 9). The decrease in GHF-1/Pit-1 binding
is specific for the TR, since other nuclear receptors do not
produce this effect. In fact, the addition of 5 mg of Cos-7 cells
transfected with an expression vector for the RA receptor
RARa did not decrease but rather increased the intensity of
the band shift formed with the GHF-1/Pit-1 binding site of the
GH promoter (Fig. 9, lane 4). These results were confirmed by
using purified proteins obtained by in vitro translation. Figure
9C shows the influence of T3 receptors on binding of the
transcription factor to its cognate site. The receptor prepara-
tion bound strongly to the TREPAL (not shown) and did not
bind to the GHF-1/Pit-1 site (Fig. 9, lane 19). However, this
preparation significantly inhibited GHF-1/Pit-1 binding (Fig. 9,
lane 21). This inhibitory effect was exerted in a ligand-inde-
pendent manner, since incubation with T3 did not modify this
inhibition (Fig. 9, lane 22). The ligand-independent effect was
also observed in an experiment similar to those described in
the legend to Fig. 9A and B, in which the T3 receptor ex-
pressed in Cos-7 cells decreased endogenous binding of 235-1
cells with the same potency in the presence and in the absence
of T3 (data not illustrated).
FIG. 7. Transcriptional repression of CRE sites by T3 in GH4C1 cells. CAT
activity was determined in cells transfected with 10 mg of a plasmid containing a
tandem repeat of CREs under the control of the TK promoter (4xCREtk-CAT).
The data are means of CAT activity for duplicate transfections determined after
the treatments whose results are shown in Fig. 5 and 6: cells were grown for 48
h in the presence or in the absence of 2 nM T3 and with 100 nM TPA or 15 mM
forskolin (FK) during the last 4 h. C, control cells.
FIG. 8. Abundance of CRE-binding proteins in T3-treated cells. Nuclear
extracts (6 mg) from control (C) untreated GH4C1 cells and cells treated with 2
nM T3 for 48 h were incubated with 32P-labeled CRE (A) or Sp1 (B) oligonu-
cleotides and analyzed by gel retardation assay. (A and B) Lanes 1 indicate the
mobility of the free probe; lanes 2 show competition with a 50-fold excess of
unlabeled oligonucleotide.
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DISCUSSION
We present evidence that the thyroid hormone T3 negatively
regulates the expression of the gene encoding the pituitary-
specific transcription factor GHF-1/Pit-1. The dose depen-
dence of the T3-caused decrease of GHF-1/Pit-1 mRNA levels
is compatible with a TR-mediated effect, since the half-maxi-
mal inhibition was found at T3 concentrations coincident with
the Kd of T3-receptor binding, and a maximal effect was ob-
tained at the concentrations which fully occupy the receptors
(45, 55). That repression of GHF-1/Pit-1 gene expression re-
quires the presence of functional amounts of TR is confirmed
by the finding that we have not observed regulation of the
GHF-1/Pit-1 gene by T3 in lactotrophic 235-1 cells that have
very low T3 receptor levels (unpublished observations).
The inhibition of GHF-1/Pit-1 expression by T3 was rather
unexpected, since thyroid hormone has been shown to tran-
scriptionally stimulate expression of the GH gene (54), which,
on the other hand, absolutely requires the presence of this
factor to be transcribed in pituitary cells (19, 26, 35, 49, 53).
However, even though a major function of T3 in somatotrophic
cell function is the stimulation of GH gene expression, in vivo
observations with rats show that in the hyperthyroid state there
is not an increase in pituitary GH content above control eu-
thyroid levels. In fact, we have observed that chronic hyper-
thyroidism leads to a decrease in GH content (41). Data ob-
tained by using cultured pituitary cells also show a rapid
increase in GH transcription rate which is maximal after 4 h of
incubation with T3 and then decreases (55). Although this
reduction has been attributed to a partial depletion of TR
levels by its own ligand, our data suggest that at longer incu-
bation times a decrease in GHF-1/Pit-1 gene expression could
also contribute to the lower velocity of GH gene transcription.
The evidence that thyroid hormone has a dual effect on GH
gene expression—inducing transcription by binding to the
TRE present in the promoter region and interfering with the
synthesis of the transcription factor binding to this region—
suggests the existence of a negative regulatory mechanism
which could attenuate the stimulation of the GH gene in the
presence of excess amounts of thyroid hormones.
Negative regulation of the GHF-1/Pit-1 gene by T3 occurs at
a transcriptional level and is mediated by sequences located in
the 59-flanking region of the gene. We have investigated the
mechanism by which T3 negatively regulates expression of the
transcription factor. The data presented here suggest a mech-
anism that does not involve interaction between the receptor
and a DNA-responsive element, since the fragment of the
promoter that mediates the T3 effect does not contain any of
the previously identified negative TRE sequences that mediate
transcriptional repression by thyroid hormone (39). Thus, T3
could repress GHF-1/Pit-1 gene expression by interfering with
transcriptional activation induced by other factors that bind to
the promoter. This promoter contains a GHF-1/Pit-1 binding
site which mediates the positive autoregulation of its own ex-
pression and two CREs (34). A fragment of the promoter
which contains only the GHF-1/Pit-1 binding site shows some
negative regulation by T3, but the fragment containing the
CRE sequences is much more strongly repressed by the hor-
mone. In consequence, the CREs were good candidates to be
involved in the negative effect of thyroid hormone. That this is
indeed the case is suggested by the finding that T3 significantly
antagonizes the induction of GHF-1/Pit-1 promoter activity by
cAMP and phorbol esters. The existence of extensive cross-talk
between the protein kinase A and C pathways is well docu-
mented (7, 11, 32, 46, 59), and our data show that stimulation
of GHF-1/Pit-1 gene expression by TPA is not mediated by a
tumor promoter response element or AP-1 binding site (3) but
rather by the CRE sequences that mediate transcriptional reg-
ulation by cAMP. Direct proof of the involvement of these
motifs in the regulation by T3 and TPA was obtained with
mutant promoters from which the CREs have been deleted.
FIG. 9. The T3 receptor antagonizes binding of GHF-1/Pit-1 to DNA elements. Gel retardation analysis was performed with the positive autoregulatory element
of the GHF-1/Pit-1 promoter (B) or the proximal binding element in the rat GH promoter (A and C). (A and B) Nuclear extracts (6 mg) from 235-1 cells which contain
endogenous GHF-1/Pit-1 or HeLa cells which do not contain this factor were incubated with 5 mg of Cos-7 cells transfected with an expression vector for TR or RAR
or with an empty expression vector (2). The reaction mixtures were incubated with the corresponding 32P-labeled GHF-1/Pit-1 binding site and analyzed by the gel
retardation assay. The mobility of the unretarded probes is shown in lanes 1 and 10, and lanes 2 and 12 show competition of lanes 3 and 13 with an excess of unlabeled
DNA. Lanes 6 and 15 show the band shift produced by the 235-1 cell extracts in the absence of Cos-7 extracts, and lane 16 shows that Cos-7 cell extracts do not produce
retardation. (C) In vitro translated GHF-1/Pit-1 (1.5 ml) was incubated with the oligonucleotide in the presence of 3.5 ml of unprogrammed reticulocyte lysate (lane
20) or the same amount of in vitro translated T3 receptor (lane 21). In lane 22, the reaction mixture of lane 20 was incubated in the presence of 100 nM T3. Neither
the lysate (lane 18) nor the receptor (lane 19) retarded the probe whose mobility is shown in lane 17.
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Deletion of either CRE greatly decreases the inhibitory effect
of T3 and profoundly inhibits stimulation by TPA or forskolin.
These findings have also been confirmed with a heterologous
promoter containing a tandem of CRE sequences. The tumor
promoter stimulated at least as strongly as cAMP its activity in
GH4C1 cells, and T3 had a repressive effect which was iden-
tical to that caused in the GHF-1/Pit-1 promoter. Taken to-
gether, our results stress the importance of the CREs in GHF-
1/Pit-1 gene expression, since in these elements the positive
regulation by the protein kinase A and C pathways and the
negative regulation by the TRs converge. The CREs have also
been recently shown to mediate the effects of the glucocorti-
coid receptor in the regulation of GHF-1/Pit-1 promoter ac-
tivity (28). Phorbol esters act in combination with glucocorticoids
to enhance expression from this promoter, and sequences con-
taining both CREs are required for this cooperation.
The T3 receptor could cause transcriptional interference
with the activity of the CREs through direct DNA-protein or
protein-protein interactions. Our DNA binding experiments
indicate that the T3 receptor does not bind directly to the CRE
sequences. These results, in which the T3 receptors antagonize
transcriptional stimulation mediated by CRE sequences with-
out binding to these elements, are reminiscent of previous
observations obtained with AP-1 binding sites. The T3 recep-
tor and the AP-1 complex antagonize each other’s activity by a
mechanism that does not require protein-DNA interaction but
rather appears to involve a direct protein-protein interaction
(60). A possible interpretation of our results would be the
existence of interaction between the receptors and the tran-
scription factor CREB, although direct proof of this mecha-
nism is still lacking. However, Jun (heterodimerizing with
CREB) and the CCAAT/enhancer-binding protein (C/EBP)
also recognize CRE sequences (4, 42), and these proteins
could, therefore, participate in this interaction. Mutual antag-
onistic effects of CREB and the glucocorticoid receptor have
been previously described (1, 13, 20, 51). This repression had
been attributed to the presence of overlapping binding sites for
CREB and the receptors in the regulated promoter (1). How-
ever, more recent reports suggest that the repression is caused
by receptor interactions with CREB or associated transcription
factors (13) or even by competition for a mutually required
target protein (51).
T3 could act more indirectly by influencing the expression of
the CRE-binding proteins. However, our experiments using gel
retardation analysis also show that there is not a decrease in
the total concentration of CRE-binding proteins in the cells
incubated with the hormone and that, additionally, an excess of
CREB does not reverse this inhibition. It remains possible that
the thyroid hormone could antagonize the effect of cAMP or
phorbol esters by modulating the activity (i.e., by changes in
the phosphorylation) of the transcription factors bound to the
CREs.
Our results also demonstrate that the autoregulatory ele-
ment plays a role in the negative regulation of GHF-1/Pit-1
promoter activity by T3. Deletion of this element from a con-
struct which also lacks the CREs abolishes T3-mediated re-
pression. The finding that the hormone still has an inhibitory
effect on the activity of the 290rGHF1-CAT construct is con-
sistent with a reduced stimulation of this autoregulatory ele-
ment by the decreased endogenous levels of the transcription
factor in hormone-treated cells. Additionally, in vitro incuba-
tion of nuclear cell extracts with T3 receptors results in a
significant decrease in GHF-1/Pit-1 binding to its cognate
DNA element, which can contribute to the observed regula-
tion. The presence of the ligand is not required for this in vitro
effect of the receptor, suggesting the existence of hormone-
independent mechanisms in this regulation. Since the receptor
does not bind to this sequence, a protein-protein interaction
between the T3 receptor and the transcription factor, leading
to a loss of binding of GHF-1/Pit-1, as occurs with the receptor
and the AP-1 complex (60), is the most likely explanation for
these observations.
In conclusion, by our investigation of the regulation of the
transcription factor GHF-1/Pit-1 we have provided evidence
for a novel negative regulatory function of the TR that is not
mediated by a classical mechanism of binding to a DNA-re-
sponsive element but rather involves transcriptional interfer-
ence with other regulatory elements. The transcriptional re-
pression of this gene provides a new example of the cross-talk
between the nuclear receptors and the membrane signal trans-
duction pathway and indicates the complexity of this interac-
tion that includes both protein kinase A- and protein kinase
C-dependent mechanisms.
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